Catalyst Wire Dossier Catalyst Wire Dossier

Lebrikizumab

lebrikizumab · Almirall, S.A.
Drug timelines are a Plus or Pro feature.

46 regulatory and trial events tracked for Lebrikizumab, covering 2015-03-05 to 2026-08-20. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis [Phase 3]

See pricing